

Diversification Update at 30/06/2012

TOBAM's Diversification Ratio (DR) ¹ measures to what extent a portfolio is diversified. The DR ² (square of the diversification ratio) corresponds to the number of independent degrees of freedom in a particular portfolio – or the number of independent variables at work. As the table shows, the “broad market” indices leave diversification on the table. In addition to a snapshot of each market's DR ² , the table shows the DR ² of a well-diversified portfolio, and the fraction of available diversification used by the index.		<i>DR² - Index diversification</i>	<i>DR² - Maximum diversification</i>	<i>% diversification used by index</i>
	MSCI EMU	1.66	3.65	46%
	MSCI US	1.72	3.76	46%
	MSCI UK	1.77	2.77	64%
	MSCI Japan	2.40	7.90	30%
	MSCI World	2.24	5.15	43%
	MSCI Australia	1.72	2.92	59%
	MSCI Emerging ²	2.90	4.27	68%

1st anniversary update: Maximum diversification in emerging markets

Since the launch of the TOBAM Anti-Benchmark Emerging Markets Equity fund on June 29, 2011, global emerging markets have had a turbulent ride. With over \$150 million in the fund as of June 29, 2012, marking its first full year of live track record, the Anti-Benchmark Emerging Markets Equity fund has achieved its objective of capturing the emerging markets equity risk premium with lower risk, by applying TOBAM's patented Anti-Benchmark methodology to maximize diversification across the investment universe.

Live Track Record

Against a backdrop of turbulent markets for most of 2011 and well into 2012 TOBAM's Anti-Benchmark Emerging Markets Equity strategy remained focused on selecting the most diversified mix of stocks in the universe. For the inception-to-date period, the 12 months ended June 28, 2012, this strategy paid off as the fund has outperformed the MSCI EM benchmark by 6.17%, with close to 18% less volatility, as detailed below.

USD 6/30/2011 - 6/28/2012	Anti-Benchmark EM Equity	MSCI Emerging Market TR Net	Improvement
Performance	-8.77%	-14.94%	6.17%
Volatility	19.42%	23.66%	-17.92%
TE / MSCI EM	7.22%		

¹TOBAM's Diversification Ratio measures a portfolio's or index's diversification. It is supported by original research and is based on a mathematical definition of diversification. TOBAM's "Anti-Benchmark" Most Diversified Portfolio[®] maximizes this Diversification Ratio. Maximizing diversification within a universe of securities provides a result closer to the true market risk premium from that universe. "Maximum Diversification[®]" and "MaxDiv[®]" are registered trademarks of TOBAM.

² The Anti-Benchmark Emerging Markets Equity strategy filters the reference index to the 200 largest market capitalizations.

AB Emerging: a better diversifier vs. MSCI EM and MSCI World...

Most investors would not question the benefits of allocating to Emerging Markets for diversification, but the table below shows that reaping the entire diversification potential of Emerging Markets requires going further than the MSCI index. The table compares correlations among the MSCI World and MSCI Emerging Markets indices, and the AB Emerging Markets portfolio:

Global and emerging markets equities correlations:

Anti-Benchmark Emerging Markets vs. the MSCI EM and MSCI World

Year ending June 29, 2012 (daily data)

Investment Universe	MSCI World	MSCI Emerging	AB EM
MSCI World	100%		
MSCI Emerging	73%	100%	
AB Emerging	60%	93%	100%


The MSCI Emerging Markets index's 73% correlation to the MSCI World index is significantly higher than the 60% correlation between the AB Emerging Markets portfolio and the MSCI World. This can be attributed to the MSCI Emerging Markets index's high exposure to two of the most globally-influenced industry sector groups, Financials and Energy/Materials. It should be no surprise that these sectors account for over 55% of index volatility, a trend similar to that seen in developed equity markets.

The AB Emerging Markets portfolio, which explicitly seeks to avoid such biases, is thus significantly more diversifying than the MSCI Emerging Markets index. Choosing emerging markets for diversification and performance should imply choosing a truly diversified emerging markets portfolio to ensure that the two objectives are met.

Most investors associate emerging markets – rife with geopolitical, sector and idiosyncratic risk – with potentially higher returns, but higher risk – a multitude of risk factors that make for a greater diversification potential. Indeed, the diversification gap between the benchmark and the Most Diversified Portfolio is structural, as illustrated by the DR2s in the following chart: only 68% of available diversification was used by the benchmark as of June 30, 2012 (the gray shaded area indicates live performance history).

Long-term diversification compared to the MSCI EM index

DR2s for the AB Emerging Markets strategy and the MSCI EM index



Anti-Benchmark Emerging Markets: robust and cost-effective for the long term

A number of implementation difficulties can confront traditional emerging markets equity investors. First, the task of researching every single emerging market stock across regions can be cost prohibitive and even confine managers to a regional specialization, whereas the opportunity set is global. Especially in a market whose macroeconomic and revenue dynamics are constantly changing, it is critical to be able to tap into all of the available sources of risk premium.

Next, traditional emerging market managers also risk subjecting their portfolios to the index's significant price swings at each index rebalancing. An additional roadblock to effective emerging markets equity implementation is limited capacity. Anti-Benchmark implementation both bypasses the cap-weighted index's bets and the capacity problems inherent in managing against this index. The Anti-Benchmark is not only indifferent to the cap-weighted index composition, and thus to its implementation challenges, but it is also relatively indifferent to which securities are included; the AB can hold different mixes of stocks yet remain very well diversified.

A third compelling argument for the Anti-Benchmark approach is its inherent efficiency. By applying a systematic methodology that targets maximum diversification while optimizing turnover and penalizing illiquidity, the Anti-Benchmark portfolio delivers a highly scalable and cost-effective portfolio. We feel that this unbiased investment methodology can be most rewarding for investors, both in terms of cost and accessibility.

As such, a portfolio that maximizes diversification across the stocks in the emerging markets equity universe can deliver the full equity risk premium to investors. The most diversified emerging markets equity portfolio has shown its ability to tap into the different risk factors underlying these (albeit volatile) equity returns, which translates into a win-win investment strategy: reaping greater investment returns while reducing portfolio risk.

For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's flagship Anti-Benchmark® strategies, supported by original research and a mathematical definition of diversification, provide clients with diversified core equity exposure, both globally and in domestic markets. FTSE also publishes the FTSE TOBAM Maximum Diversification Index Series based on the Anti-Benchmark equity portfolio construction methodology. The company manages over \$2.3 billion via its Anti-Benchmark strategies for institutional clients worldwide. Its team includes seventeen financial professionals based in Paris, Los Angeles and Amsterdam (30.06.2012).

Contacts:

Head of Business Development

Christophe Roehri
+33 1 53 23 41 60
Christophe.Roehri@tobam.fr

TOBAM North America

Steve Sapra, Ph.D., CFA
+1 646 240 4660
Steve.Sapra@tobam.fr

Benelux

Morella Hessels
+31 203 012 106
Morella.Hessels@tobam.fr

United Kingdom

Laura Vu Thien
+33 1 53 23 41 65
Laura.VuThien@tobam.fr

Client Service

Elizabeth Breaden
Tel. +33 1 53 23 41 56
ClientService@tobam.fr

TOBAM Marketing Partners

Nordics - Paxstone Capital LLP

Kasper Kemp Hansen
Tel. +45 36 95 97 00
kasper.hansen@paxstone.com

Canada - Investeam

Nancy Nightingale
Tel. +1 416 860 9490
nancy.nightingale@investeam.ca

Australia & NZ - Phoenix Capital Advisory Ltd.

Mark Jackson mark.jackson@phoenixcap.com.au
Matthew Wormald matt.wormald@phoenixcap.com.au
Tel. +612 9947 9781

Disclaimers

This document is intended for professional investors only. This document is confidential and may not be reproduced in any form without the express permission of TOBAM and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. While TOBAM believes that the information is correct at the date of production, no warranty or representation is given to this effect and no responsibility can be accepted by TOBAM to the recipient of this document or end users for any action taken on the basis of the information contained herein. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. No reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness. Opinions expressed herein reflect the opinion of TOBAM and are subject to change without notice. This document is for information purposes and does not constitute advice or a recommendation to enter into any transaction or an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same. The fund(s) that may be mentioned in this email or document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. Before entering into any transaction, you should consider the suitability of the transaction to your particular circumstances and independently review (with your professional advisers as necessary) the specific financial risks as well as the legal, regulatory, credit, tax and accounting consequences of entering into such transaction. The value and the income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested. Past performance is not indicative of future results.

Copyrights: All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws.

Trademarks: "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name.

Patents: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending.

Knowledge, processes and strategies: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws.

Terms of use: TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.

This document is issued by TOBAM which is authorized and regulated by the Autorité des Marchés Financiers ("AMF").